ANI Pharmaceuticals has completed its acquisition of US niche generics firm Novitium Pharma, which was announced in March this year. ANI expects the acquisition to enhance the scale of its contract development and manufacturing organization business and US manufacturing capacity, gaining nine of Novitium’s CDMO customers through the acquisition alongside access to its 50,000 sq ft manufacturing facility in East Windsor, New Jersey.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?